188 related articles for article (PubMed ID: 22110135)
1. Functional blockade of the voltage-gated potassium channel Kv1.3 mediates reversion of T effector to central memory lymphocytes through SMAD3/p21cip1 signaling.
Hu L; Gocke AR; Knapp E; Rosenzweig JM; Grishkan IV; Baxi EG; Zhang H; Margolick JB; Whartenby KA; Calabresi PA
J Biol Chem; 2012 Jan; 287(2):1261-8. PubMed ID: 22110135
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
Hu L; Pennington M; Jiang Q; Whartenby KA; Calabresi PA
J Immunol; 2007 Oct; 179(7):4563-70. PubMed ID: 17878353
[TBL] [Abstract][Full Text] [Related]
3. Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes.
Hu L; Wang T; Gocke AR; Nath A; Zhang H; Margolick JB; Whartenby KA; Calabresi PA
PLoS One; 2013; 8(1):e54267. PubMed ID: 23382885
[TBL] [Abstract][Full Text] [Related]
4. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
Wulff H; Calabresi PA; Allie R; Yun S; Pennington M; Beeton C; Chandy KG
J Clin Invest; 2003 Jun; 111(11):1703-13. PubMed ID: 12782673
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model.
Li Z; Liu WH; Han S; Peng BW; Yin J; Wu YL; He XH; Li WX
J Biol Chem; 2012 Aug; 287(35):29479-94. PubMed ID: 22761436
[TBL] [Abstract][Full Text] [Related]
6. Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.
Gocke AR; Lebson LA; Grishkan IV; Hu L; Nguyen HM; Whartenby KA; Chandy KG; Calabresi PA
J Immunol; 2012 Jun; 188(12):5877-86. PubMed ID: 22581856
[TBL] [Abstract][Full Text] [Related]
7. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
8. Normal human CD4(+) helper T cells express Kv1.1 voltage-gated K(+) channels, and selective Kv1.1 block in T cells induces by itself robust TNFα production and secretion and activation of the NFκB non-canonical pathway.
Fellerhoff-Losch B; Korol SV; Ganor Y; Gu S; Cooper I; Eilam R; Besser M; Goldfinger M; Chowers Y; Wank R; Birnir B; Levite M
J Neural Transm (Vienna); 2016 Mar; 123(3):137-57. PubMed ID: 26611796
[TBL] [Abstract][Full Text] [Related]
9. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.
Zhao Y; Huang J; Yuan X; Peng B; Liu W; Han S; He X
Toxins (Basel); 2015 May; 7(5):1749-64. PubMed ID: 25996605
[TBL] [Abstract][Full Text] [Related]
10. The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies.
Pérez-Verdaguer M; Capera J; Serrano-Novillo C; Estadella I; Sastre D; Felipe A
Expert Opin Ther Targets; 2016; 20(5):577-91. PubMed ID: 26634786
[TBL] [Abstract][Full Text] [Related]
11. Targeting effector memory T-cells with Kv1.3 blockers.
Wulff H; Pennington M
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):438-45. PubMed ID: 17659485
[TBL] [Abstract][Full Text] [Related]
12. T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers.
Fung-Leung WP; Edwards W; Liu Y; Ngo K; Angsana J; Castro G; Wu N; Liu X; Swanson RV; Wickenden AD
PLoS One; 2017; 12(1):e0170102. PubMed ID: 28107393
[TBL] [Abstract][Full Text] [Related]
13. c-Myc regulates the CDK1/cyclin B1 dependent‑G2/M cell cycle progression by histone H4 acetylation in Raji cells.
Yang Y; Xue K; Li Z; Zheng W; Dong W; Song J; Sun S; Ma T; Li W
Int J Mol Med; 2018 Jun; 41(6):3366-3378. PubMed ID: 29512702
[TBL] [Abstract][Full Text] [Related]
14. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
Ueyama A; Imura K; Kasai-Yamamoto E; Tai N; Nagira M; Shichijo M; Yasui K
Clin Exp Dermatol; 2013 Dec; 38(8):897-903. PubMed ID: 24252082
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of Kcna3-encoding Kv1.3 potassium channel by cereblon contributes to regulation of CD4+ T-cell activation.
Kang JA; Park SH; Jeong SP; Han MH; Lee CR; Lee KM; Kim N; Song MR; Choi M; Ye M; Jung G; Lee WW; Eom SH; Park CS; Park SG
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8771-6. PubMed ID: 27439875
[TBL] [Abstract][Full Text] [Related]
16. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
Beeton C; Wulff H; Standifer NE; Azam P; Mullen KM; Pennington MW; Kolski-Andreaco A; Wei E; Grino A; Counts DR; Wang PH; LeeHealey CJ; S Andrews B; Sankaranarayanan A; Homerick D; Roeck WW; Tehranzadeh J; Stanhope KL; Zimin P; Havel PJ; Griffey S; Knaus HG; Nepom GT; Gutman GA; Calabresi PA; Chandy KG
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17414-9. PubMed ID: 17088564
[TBL] [Abstract][Full Text] [Related]
17. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.
Beeton C; Smith BJ; Sabo JK; Crossley G; Nugent D; Khaytin I; Chi V; Chandy KG; Pennington MW; Norton RS
J Biol Chem; 2008 Jan; 283(2):988-97. PubMed ID: 17984097
[TBL] [Abstract][Full Text] [Related]
18. Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease.
Valverde P; Kawai T; Taubman MA
J Dent Res; 2005 Jun; 84(6):488-99. PubMed ID: 15914584
[TBL] [Abstract][Full Text] [Related]
19. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.
Azam P; Sankaranarayanan A; Homerick D; Griffey S; Wulff H
J Invest Dermatol; 2007 Jun; 127(6):1419-29. PubMed ID: 17273162
[TBL] [Abstract][Full Text] [Related]
20. Blockade of Kv1.3 potassium channel inhibits CD8
Zhao Y; Qiu W; Liu J; Yuan X; Mao W; Yin J; Peng B; Liu W; Han S; He X
FASEB J; 2020 Nov; 34(11):15492-15503. PubMed ID: 32981181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
